About PierianDx
PierianDx is a Healthcare company based in Saint Louis (United States) founded in 2014 by Rakesh Nagarajan, and was acquired by Velsera in January 2023. Genetic tests for individualized disease diagnosis are provided. PierianDx has raised $69.35 million across 8 funding rounds from investors including Inova, RTI International and Orbimed. The company has 234 employees. PierianDx has completed 1 acquisition, including Tute Genomics. Its Indian entity Pieriandx India Private Limited reported revenue of ₹51.52 Cr. PierianDx offers products and services including Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include ArcherDX, Personalis and Variantyx; 3 of its 3 listed competitors have raised funding.
Company details
PierianDx was founded in 2014 in Saint Louis, United States, within the genetic testing sector. Patient-specific diagnoses and treatments for multiple diseases are delivered based on individual DNA analysis. Operations are supported by a proprietary cloud-based Clinical Genomicist Workstation software, which manages next-generation sequencing across six phases: case accessioning, sequencing, analysis, draft report, final report, and electronic health record integration.
- Headquarters Saint Louis, United States
- Employees 234
- Founders Rakesh Nagarajan
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website pieriandx.com
- Social LinkedIn X
- Acquired by Velsera (Jan 2023)
- Legal Name Pieriandx India Private Limited
- Date of Incorporation 07 Jan, 2016
- Jurisdiction Pune, Maharashtra, India
Associated legal entities of PierianDx
PierianDx operates through Pieriandx India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Pieriandx India Private Limited CIN U73100PN2016FTC157856 | Active | 07 Jan 2016 | Pune, Maharashtra | ₹51.5 Cr | 234 | 3 | View details |
Products & Services of PierianDx
PierianDx offers a comprehensive portfolio of products and services, including Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships.
Software for analyzing and interpreting genomic data in clinical settings.
Curated resource for accurate variant interpretations and treatment options.
Support for genomics workflows and assay validation processes.
Services for integrating genomic reporting in IVD assays.
Funding Insights of PierianDx
PierianDx has successfully raised a total of $69.35M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $69.35M
- Total Rounds 8
- Investors Count 9
All 8 funding rounds of PierianDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | Debt – Conventional | – | – | ||
| Nov 2021 | $30M | Series C | – | Orbimed | |
| Jun 2021 | Series B | – | – | ||
| Oct 2019 | $27M | Series B | – | ATW Partners, SJF Ventures | |
| Apr 2018 | Series A | – | – | ||
| Feb 2018 | $3.1M | Series A | – | – | – |
| Jan 2016 | $9.25M | Series A | – | Health Catalyst Capital | |
| Jun 2015 | Seed | – | Meyer and Co |
10 investors in total: 10 institutional.
Investors in PierianDx
PierianDx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Inova, RTI International and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Growth-stage US tech companies are funded by Health Catalyst Capital. | healthcatalystcapital.com | New York, United States | ||
ATW Partners is engaged in smart and strategic investing. | atwpartners.com | New York, United States | ||
Impact venture capital is invested in early-stage US companies. | sjfventures.com | Durham, United States | ||
Growth-stage investments are targeted by this VC firm. | meyerandco.com | New York, United States | ||
| frazier.vc | ||||
Research institute for improving the human condition by turning knowledge into practice | 1958 | rti.org | United States | |
Multi-specialty hospitals are operated throughout the United States. | 1956 | inova.org | United States | |
Clinical laboratory testing and healthcare advisory services are provided. | 1999 | aruplab.com | Salt Lake City, United States | |
AI-based omic data analysis tool for researchers | 2022 | velsera.com | Boston, United States |
Investor details for PierianDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Pieriandx India Private Limited (PierianDx)
Pieriandx India Private Limited is the primary company behind PierianDx. The board of Pieriandx India Private Limited currently have 3 directors; the longest-serving is Rakesh Nagarajan, appointed in 2016. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rakesh Nagarajan DIN 07285883 | Director | 07 Jan 2016 | 10 yrs 9 mo | Pieriandx India Private Limited |
| Shabbir Taherbhai Pancha DIN 11152986 | Additional Director | 17 Jun 2025 | 1 yr 4 mo | Pieriandx India Private Limited |
| Sarika Udaychandra Phatak DIN 11273069 | Additional Director | 09 Sep 2025 | 1 yr 1 mo | Pieriandx India Private Limited |
People of PierianDx
19 people are tracked at PierianDx (4 in leadership, 15 in team); the tracked headcount is 234.
| Name | Role | Group |
|---|---|---|
| Founder | Leadership | |
Rupali Pathak, PHR | Director HR - People Operations India | Leadership |
Saurav Lahiri | Director DevOps & IT | Leadership |
Mukesh Sharma | Vice President - Product | Leadership |
Manojkumar Patil | Project Manager | Team |
Abhishek Mandke | Associate Accountant | Team |
Jordan Thompson | Marketing Specialist | Team |
Snehal Patil | Senior Quality Assurance Engineer | Team |
Amrut Dengre | Senior DevOps Engineer | Team |
Ciara' Hargis | Marketing Communications & Event Coordinator | Team |
Nilam Satpute | Senior Accountant | Team |
Lambert Fru | Sr DevOps Engineer | Team |
Deepankar Sinha | Software Engineer | Team |
Arth Anjaria | Associate QA Engineer - Bioinformatics | Team |
Arshiya G | QA Bioinformatics Engineer | Team |
Pamela Hesker | Sr. Product Specialist | Team |
Shantanu Patwardhan | Senior Software Engineer | Team |
Ankita Parikh | Technical Lead | Team |
Rundan Patre | System Administrator | Team |
Complete people profiles for PierianDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of PierianDx
Figures of Pieriandx India Private Limited, the primary company behind PierianDx, for FY 2025. Revenue was ₹51.52 Cr (-2% year on year). Net profit was ₹4.22 Cr (8% margin). EBITDA was ₹6.64 Cr (13% margin). Revenue has grown at a compounded annual rate of +14% over three years and +28% over five years.
- ₹51.52 CrRevenue · FY 2025 · -2% YoY
- ₹4.22 CrNet profit · 8% margin
- ₹6.64 CrEBITDA · 13% margin
- ₹15 LakhPaid-up capital
- 234Employees (provident fund records)
- +14%Revenue CAGR, 3 years
- +28%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Pieriandx India Private Limited are on its company page.
Detailed financial statements for PierianDx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PierianDx
PierianDx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tute Genomics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cloud-based genome analysis for precision medicine is provided. | tutegenomics.com | Los Angeles, United States | 2012 | Oct 2016 | •••• |
Complete acquisition details for PierianDx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of PierianDx
5 dated milestones of PierianDx across 9 years, from founding to its latest funding, stage changes and deals.
- Founded PierianDx is founded.
- Funding First funding round.
- Acquisition Acquires Tute Genomics.
- Funding Latest funding round, Debt – Conventional,.
- Exit Acquired by Velsera.
Competitors of PierianDx
PierianDx has 3 listed competitors in our database, 3 of them funded. They include ArcherDX, Personalis and Variantyx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| variantyx.com | 2014 | Boston, United States | $110.5M | 122 | Genomics data analysis platform for healthcare diagnostics is offered. |
Detailed competitors of PierianDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PierianDx
The website of PierianDx (pieriandx.com) receives about 3.4K visits a month and ranks #1,281,049 among all websites worldwide, #1,633 in Biotechnology and Pharmaceuticals.
- Monthly visits3.4K
▼ 64.7% vs previous month
- Unique visitors2.3K
per month
- Global rank#1,281,049
among all websites
- Category rank#1,633
Health · Biotechnology and Pharmaceuticals
- Bounce rate27%
- Pages per visit13.2
- Average visit14 min 02 sec
- DevicesDesktop 82% · Mobile 18%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as PierianDx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pieriandx
Complete news archive for PierianDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PierianDx
PierianDx was founded in 2014 and raised its 1st funding round 1 year after it was founded.
PierianDx is headquartered in Saint Louis, United States. It is registered at Saint Louis, Missouri, United States.
PierianDx is a funded company, having raised a total of $69.35M across 8 funding rounds to date.
PierianDx has 234 employees.
The primary company behind PierianDx, Pieriandx India Private Limited, reported revenue of ₹51.52 Cr for FY 2025, down 2% year on year.
PierianDx was founded in 2014 in Saint Louis, United States, within the genetic testing sector. Patient-specific diagnoses and treatments for multiple diseases are delivered based on individual DNA analysis. Operations are supported by a proprietary cloud-based Clinical Genomicist Workstation software, which manages next-generation sequencing across six phases: case accessioning, sequencing, analysis, draft report, final report, and electronic health record integration.
PierianDx's top competitors include Personalis, ArcherDX and Variantyx.
PierianDx offers Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, and IVD Partnerships.
PierianDx has made 1 acquisition, including Tute Genomics.
PierianDx has 10 investors. Key investors include Inova, RTI International, Orbimed, ARUP Laboratories, and Velsera.
PierianDx operates through Pieriandx India Private Limited.
Yes. PierianDx was acquired by Velsera in January 2023.